Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Inventory (2018 - 2025)

BioNexus Gene Lab's Inventory history spans 8 years, with the latest figure at $676703.0 for Q4 2025.

  • Quarterly results put Inventory at $676703.0 for Q4 2025, down 51.27% from a year ago — trailing twelve months through Dec 2025 was $676703.0 (down 51.27% YoY), and the annual figure for FY2025 was $676703.0, down 51.27%.
  • Inventory for Q4 2025 was $676703.0 at BioNexus Gene Lab, down from $1.0 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $1.7 million in Q2 2021 to a low of $676703.0 in Q4 2025.
  • The 5-year median for Inventory is $1.2 million (2023), against an average of $1.2 million.
  • The sharpest move saw Inventory surged 20274.32% in 2021, then crashed 51.27% in 2025.
  • Year by year, Inventory stood at $1.5 million in 2021, then tumbled by 35.75% to $977807.0 in 2022, then grew by 16.36% to $1.1 million in 2023, then grew by 22.05% to $1.4 million in 2024, then crashed by 51.27% to $676703.0 in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $676703.0, $1.0 million, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.